RxDoctor Payments Data

Sheralene Ng, MD

Internal Medicine · Redding, CANPI 1174546840

Payments from drug & device makers

$614in general payments, 2019–2025

Across 7 payments — averaging $87.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$283
  • Boehringer Ingelheim$115
  • Janssen Products, LP$77
  • GSK$73
  • Medtronic$66

What the payments were for

  • Food & beverage$614100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead3$283
Boehringer Ingelheim1$115
Janssen Products, LP1$77
GSK1$73
Medtronic1$66

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$614 in reported general payments places this provider in the 70th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$318,092
Medicare patients
571
Services billed
3,958

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban53$64,312
OzempicSemaglutide35$30,940
JanuviaSitagliptin Phosphate16$26,086
JardianceEmpagliflozin22$19,715
MyrbetriqMirabegron11$12,962
Combivent RespimatIpratropium/Albuterol Sulfate13$8,176
Wixela InhubFluticasone Propion/Salmeterol29$6,007
Levothyroxine Sodium451$6,002
Gabapentin154$4,510
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$4,034
Losartan Potassium316$3,491
Atorvastatin Calcium355$3,459
Potassium Chloride120$3,037
Duloxetine Hcl73$2,756
Amlodipine Besylate348$2,452

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$115$27,89135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Redding

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →